t-cell bispecifics in aml: ongoing challenges and future outlooks
Published 1 year ago • 339 plays • Length 2:22Download video MP4
Download video MP3
Similar videos
-
1:10
how bispecific antibodies contribute to t-cell activation in aml
-
1:04
t-cell bispecific antibody targeting intracellular wt1 in aml
-
2:43
t-cell engaging treatment in aml
-
1:24
t-cell engaging antibodies: what lessons have we learnt?
-
1:02
bispecific agents: the future of aml and mds treatment?
-
3:13
targeting cd38 with a bispecific antibody to treat r/r aml: a phase i trial
-
1:23
improving the efficacy of bispecific antibodies in aml
-
11:14
antibodies and bacteria
-
18:55
mixed leukocyte reaction and other antigen-presentation assays [webinar]
-
54:19
antigen-specific t cells [webinar]
-
5:35
clinical and prognostic significance of aberrant t-cell marker expression in aml
-
1:36
bispecific antibodies for r/r aml: ongoing clinical trials
-
3:01
t-cell engaging antibodies: novel combinations to overcome resistance
-
2:13
haploidentical sct for the treatment of secondary aml
-
6:47
novel antibodies in aml
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml
-
1:41
lava-051: a novel bispecific t-cell engager for r/r hematological malignancies
-
5:30
linvoseltamab versus teclistamab for tce rrmm and the sequencing of bispecifics with car-ts
-
8:57
outcomes of sct in t-all and t-lbl
-
2:41
cell avidity as a predictor of t-cell efficacy
-
3:27
the mechanism of bispecific t-cell engagers in b-all: genomic alterations
-
1:04
horizon scan of novel and upcoming aml therapies